Item 7.01 Regulation FD.
On January 25, 2023, QSAM Biosciences, Inc. (the “Company”) participated in the
Emerging Growth Conference. Douglas Baum, our CEO, presented at the virtual
conference, using the presentation furnished as Exhibit 99.1 to this report and
incorporated herein by reference. The Company may use the presentation and/or
webcast of the presentation, possibly with modifications, in future
presentations to current and potential investors, analysts, lenders, business
partners, acquisition candidates, customers, employees and others with an
interest in the Company and its business.
A copy of the presentation is also available on the Company’s website at
https://ir.qsambio.com/. Materials on the Company’s website are not part of or
incorporated by reference into this report.
In accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liability of that
section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are filed with this Current Report on Form 8-K:
Exhibit Number Description
99.1 QSAM Biosciences, Inc. corporate presentation, dated January
25, 2023.
104 Cover Page Interactive Data File (the cover page XBRL tags are
embedded within the inline XBRL document).
© Edgar Online, source Glimpses
postbrexitcompliance.com 